Market Overview - The Sci-Tech Innovation Board (STAR Market) index fell by 1.24%, closing at 1328.19 points, with a total trading volume of 3.128 billion shares and a turnover of 142.69 billion yuan, resulting in a weighted average turnover rate of 1.63% [1] - Among the tradable stocks on the STAR Market, 121 stocks closed higher, with 3 stocks rising over 10% and 13 stocks rising between 5% and 10%. Conversely, 465 stocks closed lower [1] Trading Activity - The distribution of turnover rates for STAR Market stocks shows that 2 stocks had turnover rates exceeding 20%, 8 stocks had rates between 10% and 20%, 43 stocks had rates between 5% and 10%, 54 stocks had rates between 3% and 5%, 305 stocks had rates between 1% and 3%, and 181 stocks had rates below 1% [1] - C Hengkong, a newly listed stock, had the highest turnover rate at 47.40%, closing down by 3.05% with a trading volume of 1.454 billion yuan and a net outflow of 34.016 million yuan in main funds [1] - Other notable stocks include Bibet, which rose by 7.73% with a turnover rate of 21.08%, and several others like Yingfang Software, Huasheng Lithium, and Weidao Nano, with turnover rates of 18.95%, 13.99%, and 13.26% respectively [1] High Turnover Stocks - Among stocks with a turnover rate exceeding 5%, C Hengkong is noted as a newly listed stock. In terms of market performance, 21 stocks in this category rose today, with San Da Membrane, Gongda High-Tech, and Qingyun Technology leading with increases of 13.74%, 10.80%, and 10.76% respectively. Conversely, Huasheng Lithium, Hexin Instruments, and Jindike saw declines of 9.33%, 7.43%, and 6.87% respectively [2] - The electronic industry had the highest representation among high turnover stocks, with 21 stocks, followed by the power equipment and computer sectors with 9 and 5 stocks respectively [2] Fund Flow - In terms of fund flow, 24 stocks in the high turnover category experienced net inflows, with Dekeli, Dongxin Co., and Haibo Sichuang receiving the most significant net inflows of 99.676 million yuan, 86.0429 million yuan, and 66.7609 million yuan respectively. On the other hand, Baiwei Storage, Shijia Photon, and Shijia Technology faced substantial net outflows of 276 million yuan, 141 million yuan, and 135 million yuan respectively [2] - Recent movements in leveraged funds indicate that 33 stocks have seen net purchases of leveraged funds, with Dongxin Co., Huasheng Lithium, and Huafeng Technology showing significant increases in financing balances of 294 million yuan, 261 million yuan, and 227 million yuan respectively. Conversely, Artis, Shijia Photon, and Tengjing Technology experienced notable decreases in financing balances of 136 million yuan, 113 million yuan, and 103 million yuan respectively [3] Key Stocks - The top stocks by turnover rate on November 20 include: - C Hengkong: Closing price 58.22 yuan, daily change -3.05%, turnover rate 47.40%, net outflow -34.016 million yuan [4] - Bibet: Closing price 29.98 yuan, daily change +7.73%, turnover rate 21.08%, net inflow +35.5901 million yuan [4] - Yingfang Software: Closing price 56.00 yuan, daily change +0.90%, turnover rate 18.95%, net inflow +55.9331 million yuan [4] - Huasheng Lithium: Closing price 103.99 yuan, daily change -9.33%, turnover rate 13.99%, net outflow -94.0686 million yuan [4] - Weidao Nano: Closing price 59.12 yuan, daily change -1.63%, turnover rate 13.26%, net outflow -90.0089 million yuan [4]

Group 1 - The company has approved a proposal to change its registered capital and company type, which will be submitted for review at the upcoming shareholders' meeting [1][2] - The company has completed its initial public offering (IPO) of 90 million shares, increasing its total shares from 36,003.6657 million to 45,003.6657 million and its registered capital from 36,003.6657 million RMB to 45,003.6657 million RMB [1][2] - The company type has been changed from a foreign-invested, unlisted joint-stock company to a foreign-invested, listed joint-stock company [1][2] Group 2 - The company is revising its articles of association to enhance operational standards, in accordance with relevant laws and regulations, and will eliminate the supervisory board, transferring its responsibilities to the audit committee [2][3] - The revised articles will be effective upon approval at the shareholders' meeting, and the original articles will be automatically nullified [3] - The company will disclose the revised articles on the Shanghai Stock Exchange website after the shareholders' meeting [3]

Group 1 - The company held the second supervisory board's seventh (temporary) meeting on November 11, 2025, with all three supervisors present, ensuring compliance with relevant laws and regulations [2][3][5] - The supervisory board approved the adjustment of the proposed investment amount for fundraising projects due to the actual net fundraising amount being lower than planned, ensuring no harm to the company or shareholders' interests [3][4][56] - The board also approved the use of temporarily idle fundraising funds for cash management, which is expected to enhance fund utilization efficiency and increase company revenue [7][8][44] Group 2 - The company announced the first temporary shareholders' meeting for 2025, scheduled for November 28, 2025, with a combination of on-site and online voting [17][21][29] - The meeting will discuss previously disclosed proposals, including special resolutions and voting procedures for shareholders [21][22][24] Group 3 - The company plans to use up to RMB 900 million of temporarily idle fundraising funds for cash management, focusing on high-security, liquid financial products [31][33][36] - The cash management aims to improve fund utilization efficiency while ensuring that it does not affect the implementation of fundraising projects [41][44][46] Group 4 - The company intends to use its own funds to pay for fundraising project expenses and subsequently replace them with equivalent amounts from the fundraising account, ensuring operational efficiency [61][64][67] - This approach is designed to comply with the principle of using fundraising funds specifically for their intended purpose and will not affect the normal operation of fundraising projects [67][69][72]

Core Viewpoint - Guizhou Bibet Pharmaceutical Co., Ltd. has announced the approval of a proposal to use its own funds to pay for fundraising project expenses, which will later be replaced by raised funds [1][5]. Fundraising Overview - The company completed its initial public offering (IPO) in 2025, issuing 90 million shares at a price of 17.78 yuan per share, raising a total of 1.6002 billion yuan, with a net amount of approximately 1.4911 billion yuan after deducting issuance costs [2]. Fundraising Project Details - The total investment for the three major fundraising projects amounts to 2.0046 billion yuan, with specific allocations as follows: - New drug research and development: 949.12 million yuan - Qingyuan R&D center and formulation industrialization base construction: 555.49 million yuan - Supplementing working capital: 500 million yuan [3]. Replacement Reason and Process - The core reason for using self-owned funds initially is due to restrictions on salary and tax payments during the implementation of fundraising projects. Payments for salaries, social insurance, and other related expenses must be made from the company's basic deposit accounts, not directly from the fundraising special account [3]. Operational Process - The finance department will monthly track the amounts paid with self-owned funds for the fundraising projects and will initiate replacement applications quarterly, following internal approval procedures [4]. Opinions and Impact Analysis - Independent directors believe the matter does not involve changes in the direction of fundraising and does not harm the interests of the company and shareholders. The supervisory board confirms that necessary approval procedures have been followed, which will enhance the efficiency of fundraising usage [5]. Company Impact - The operation strictly adheres to the principle of dedicated use of fundraising and will not change the direction of the funds. This approach will meet the actual needs for salary and tax payments and improve operational management efficiency. The approval of this proposal marks a substantial advancement in the fundraising projects, accelerating new drug development and construction of the R&D center [6].

广州必贝特医药股份有限公司 对外担保管理制度 第一章 总则 第一条 为了规范广州必贝特医药股份有限公司（以下简称"公司"）的对 外担保行为，有效控制公司对外担保风险，保护公司和全体股东合法权益和公司 财务安全，根据《中华人民共和国公司法》《中华人民共和国民法典》（以下简 称"《民法典》"）《上海证券交易所科创板股票上市规则》等法律、法规、规 范性文件以及《广州必贝特医药股份有限公司章程》（以下简称"《公司章程》"） 等有关规定，制定本制度。 第二条 本制度所称对外担保是指公司为他人提供的担保（包括保证、抵押 或质押等），包括公司对控股子公司提供的担保。 公司及公司控股子公司的对外担保总额，是指包括公司对控股子公司在内的 公司对外担保总额与控股子公司对外担保总额之和。 公司控股子公司或公司具有实际控制权的参股子公司的对外担保，视同公司 行为，其对外担保应执行本制度。 第三条 公司为他人提供担保应当遵循合法、审慎、互利、安全、自愿、诚 信的原则，严格控制担保风险。 第四条 公司对外担保实行统一管理，未经公司董事会或股东会批准，公司 及控股子公司不得对外提供担保，任何人无权以公司名义签署对外担保的合同、 协议或其他 ...

广州必贝特医药股份有限公司 章程 二〇二五年十一月 1 | | | 广州必贝特医药股份有限公司 章程 第一章 总则 第一条 为维护广州必贝特医药股份有限公司（以下简称"公司"）、股 东和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司 法》（以下简称"《公司法》"）、《中华人民共和国证券法》、和其他有关 规定，制订本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司。 公司系在广州必贝特医药技术有限公司的基础上，依法整体变更设立的股份 有限公司，在广州市市场监督管理局注册登记，取得营业执照，统一社会信用代 码为 91440101589519277H。 公司于 2025 年 8 月 4 日经中国证券监督管理委员会（以下简称"中国证监 会"）同意注册，首次向社会公众发行人民币普通股 9,000 万股，于 2025 年 10 月 28 日在上海证券交易所上市。 第三条 公司注册名称：广州必贝特医药股份有限公司。 英文名称：BeBetter Med Inc. 第四条 公司住所：广州市高新技术产业开发区科学城崖鹰石路 25 号 A-3 栋第八层 802 房，邮政编码：510663。 第 ...

广州必贝特医药股份有限公司 独立董事工作制度 为进一步完善广州必贝特医药股份有限公司（以下简称"公司"）治理结构， 促进公司规范运作，根据《中华人民共和国公司法》（以下简称"公司法"）《中 华人民共和国证券法》（以下简称"《证券法》"）《上海证券交易所科创板股 票上市规则》（以下简称"《科创板上市规则》"）《上市公司独立董事管理办 法》等法律法规、规范性文件以及《广州必贝特医药股份有限公司章程》（以下 简称"《公司章程》"），特制定本制度。 第一章 总则 第一条 本制度所指的独立董事，是指不在公司担任除董事外的其他职务， 并与公司及其主要股东、实际控制人不存在直接或者间接利害关系，或者其他可 能妨碍其进行独立客观判断的关系的董事。 独立董事应当独立履行职责，不受公司及其主要股东、实际控制人等单位或 者个人的影响。 第二条 独立董事对公司及全体股东负有忠实与勤勉义务。独立董事应当按 照法律、行政法规、中国证券监督管理委员会（以下简称"中国证监会"）规定、 证券交易所业务规则和公司章程的规定，认真履行职责，在董事会中发挥参与决 策、监督制衡、专业咨询作用，维护上市公司整体利益，保护中小股东合法权益。 第三条 公司 ...

广州必贝特医药股份有限公司 关联交易管理制度 第一章 总则 第一条 为规范广州必贝特医药股份有限公司（以下简称"公司"）关联交 易管理，维护公司及公司股东的合法权益，根据《中华人民共和国公司法》《企 业会计准则第 36 号——关联方披露》《上海证券交易所科创板股票上市规则》（以 下简称"《科创板股票上市规则》"）等有关法律法规及《广州必贝特医药股份有 限公司章程》（以下简称"《公司章程》"）的规定，制定本制度。 第二条 公司的关联交易是指公司或者其合并报表范围内的子公司等其他 主体与公司关联人之间发生的交易，以及可能引致资源或者义务转移的事项。 第三条 公司发生关联交易，应当保证关联交易的合法性、必要性、合理性 和公允性，保持公司的独立性，不得利用关联交易调节财务指标，损害公司利益。 第四条 公司的关联交易应当遵循以下基本原则： （一）诚实信用的原则； （二）关联股东及关联董事回避的原则； （三）符合公开、公平、公允的原则； （四）书面协议的原则，关联交易协议的签订应当遵循平等、自愿、等价、 有偿的原则，协议内容应明确、具体。 第二章 关联人和关联关系的认定 第五条 公司的关联人包括关联法人和关联自然人。 第 ...

广州必贝特医药股份有限公司 董事及高级管理人员离职管理制度 第一章 总则 第一条 为规范广州必贝特医药股份有限公司（以下简称"公司"）董事及 高级管理人员离职管理，保障公司治理稳定性及股东合法权益，根据《中华人民 共和国公司法》《中华人民共和国证券法》《上市公司治理准则》《上市公司董事 和高级管理人员所持本公司股份及其变动管理规则》等法律法规、规范性文件、 证券交易所业务规则及《公司章程》的规定，结合公司实际情况，制定本制度。 第二条 本制度适用于公司董事（含独立董事）、高级管理人员因任期届满、 辞职、被解除职务或其他原因离职的情形。 第三条 公司董事、高级管理人员离职管理应遵循以下原则： （一）合法合规原则：严格遵守国家法律法规、监管规定及《公司章程》的 要求； （二）公开透明原则：及时、准确、完整地披露董事、高级管理人员离职相 关信息； （三）平稳过渡原则：确保董事、高级管理人员离职不影响公司正常经营和 治理结构的稳定性； （四）保护股东权益原则：维护公司及全体股东的合法权益。 第二章 离职情形与程序 第四条 公司董事、高级管理人员离职包含任期届满未连任、主动辞职、被 解除职务以及其他导致董事、高级管理人 ...

广州必贝特医药股份有限公司 防范控股股东及关联方资金占用管理制度 第一章 总则 第一条 为规范广州必贝特医药股份有限公司（以下简称"公司"）与控股 股东及其他关联方的资金往来，建立防止控股股东及关联方占用公司资金的长效 机制，杜绝控股股东及关联方资金占用行为的发生，根据《中华人民共和国公司 法》《中华人民共和国证券法》《上市公司监管指引第 8 号——上市公司资金往 来、对外担保的监管要求》等法律、法规以及《广州必贝特医药股份有限公司章 程》（以下简称"《公司章程》"）《广州必贝特医药股份有限公司关联交易管 理制度》（以下简称"《关联交易管理制度》"）等有关规定，制定本制度。 第二条 本制度所称"控股股东"，是指持有的股份占公司股本总额 50％ 以上的股东；或持有股份的比例虽然不足 50%，但依其持有的股份所享有的表决 权已足以对股东会的决议产生重大影响的股东。 本制度所称"实际控制人"是指通过投资关系、协议或者其他安排能够实际 控制、影响公司行为的自然人或法人。 本制度所称"关联方"，是指根据相关法律、法规和《上海证券交易所科创 板股票上市规则》《企业会计准则第 36 号——关联方披露》所界定的关联方， 包括 ...